0001193125-22-226110.txt : 20220822 0001193125-22-226110.hdr.sgml : 20220822 20220822092203 ACCESSION NUMBER: 0001193125-22-226110 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220822 ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Changes in Control of Registrant ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220822 DATE AS OF CHANGE: 20220822 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000920465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330361285 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36282 FILM NUMBER: 221182402 BUSINESS ADDRESS: STREET 1: 201 JONES ROAD, SUITE 400 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-715-3600 MAIL ADDRESS: STREET 1: 201 JONES ROAD, SUITE 400 CITY: WALTHAM STATE: MA ZIP: 02451 8-K 1 d399465d8k.htm 8-K 8-K
LA JOLLA PHARMACEUTICAL CO NASDAQ false 0000920465 --12-31 0000920465 2022-08-22 2022-08-22

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 22, 2022

 

 

La Jolla Pharmaceutical Company

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36282   33-0361285

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

201 Jones Road, Suite 400

Waltham, Massachusetts

   02451
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 715-3600

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of exchange

on which registered

Common Stock, par value $0.0001 per share   LJPC   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Introductory Note

On August 22, 2022, Innoviva, Inc., a Delaware corporation (the “Parent”) completed the previously announced acquisition of La Jolla Pharmaceutical Company, a Delaware corporation (the “Company”), pursuant to an Agreement and Plan of Merger, dated as of July 10, 2022 (the “Merger Agreement”), by and among the Company, Parent and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the “Purchaser”).

 

Item 1.02

Termination of Material Definitive Agreement.

Effective as of August 22, 2022, and immediately following the effective time of the Merger (the “Effective Time”), the Company terminated the Company’s Amended and Restated 2013 Equity Incentive Plan and the Company’s 2018 Employee Stock Purchase Plan.

 

Item 2.01

Completion of Acquisition or Disposition of Assets.

As previously disclosed, pursuant to the Merger Agreement, Purchaser conducted a tender offer to acquire all of the issued and outstanding shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), other than any Parent-Owned Shares and Company-Owned Shares (each as defined below), at a purchase price of $6.23 per Share in cash (the “Offer Price”), without interest and subject to any applicable withholding taxes (the “Merger Consideration”), upon the terms and subject to the conditions set forth in the Offer to Purchase, dated July 25, 2022 (as amended or supplemented from time to time, the “Offer to Purchase”), and the related Letter of Transmittal (the “Letter of Transmittal” and, together with the Offer to Purchase and other related materials, as each as amended or supplemented from time to time, the “Offer”).

The Offer expired one minute after 11:59 P.M., New York City time, on August 19, 2022 as scheduled and was not extended. According to American Stock Transfer and Trust Company, LLC, the depositary for the Offer, 21,703,224 Shares were validly tendered and not withdrawn pursuant to the Offer, which Shares represented approximately 87% of the outstanding Shares, satisfying the minimum tender condition to the Offer. Each other condition to the Offer was satisfied or waived, and Purchaser irrevocably accepted for payment all Shares that were validly tendered and not validly withdrawn.

On August 22, 2022, following consummation of the Offer, Purchaser merged with and into the Company (the “Merger”), with the Company surviving as a wholly-owned subsidiary of the Parent. The Merger was completed pursuant to Section 251(h) of the General Corporation Law of the State of Delaware (the “DGCL”), with no vote of the Company stockholders required to consummate the Merger. At the effective time of the Merger (the “Effective Time”), each issued and outstanding Share (other than (i) Shares owned at the commencement of the Offer and immediately prior to the Effective Time by Parent, Purchaser or any other direct or indirect wholly-owned subsidiary of Parent (the “Parent-Owned Shares”), (ii) Shares owned immediately prior to the Effective Time by the Company (or held in the Company’s treasury) (the “Company-Owned Shares”) and (iii) Shares held by stockholders who are entitled to, and who have properly exercised and perfected their respective demands for, appraisal of such Shares in the time and manner provided in Section 262 of the DGCL and, as of the Effective Time, have neither effectively withdrawn their respective demand nor otherwise lost their respective rights to appraisal pursuant to Section 262 of the DGCL), was converted into the right to receive an amount in cash equal to the Merger Consideration, without interest and subject to any applicable withholding of taxes. Additionally, each issued and outstanding share the Company’s Series C-12 Convertible Preferred Stock, par value $0.0001 per share (each, a “Preferred Share”) (other than (i) Preferred Shares owned at the commencement of the Offer and immediately prior to the Effective Time by Parent, Purchaser or any other direct or indirect wholly-owned subsidiary of Parent, (ii) Preferred Shares owned immediately prior to the Effective Time by Parent (or held in La Jolla’s treasury) and (iii) Preferred Shares held by stockholders who are entitled to, and who have properly exercised and perfected their respective demands for, appraisal of such Shares in the time and manner provided in Section 262 of the DGCL and, as of the Effective Time, have neither effectively withdrawn their respective demand nor otherwise lost their respective rights to appraisal pursuant to Section 262 of the DGCL), was converted into the right to receive an amount in cash equal to 1,724.04 times the Merger Consideration (the “Preferred Share Consideration”), without interest and subject to any applicable withholding of taxes.

 

2

As a result of the Merger, (i) each option to purchase Shares (each, a “Company Option”), whether vested or unvested, was terminated and cancelled immediately prior to the Effective Time in exchange for the right of the holder thereof to receive a lump-sum amount in cash, without interest, equal to the excess, if any, of the Offer Price over the exercise price per share thereof, net of any taxes withheld pursuant to the Merger Agreement. With respect to each Company Option with an exercise price that is greater than or equal to the Offer Price, such termination and cancellation was for no consideration.

The foregoing summaries of the Merger Agreement and the transactions contemplated respectively thereby do not purport to be complete and are subject to, and qualified in their entirety by, the full text of the Merger Agreement, attached as Exhibit 2.1 to the Current Report on Form 8-K filed by the Company on July 11, 2022, which are incorporated herein by reference.

 

Item 3.01

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On August 22, 2022, the Company (a) notified the Nasdaq Capital Market (“Nasdaq”) of the consummation of the Merger and (b) requested that Nasdaq: (i) halt trading of the Common Stock for August 22, 2022 and suspend trading of the Common Stock effective August 22, 2022; and (ii) file with the Securities and Exchange Commission (“SEC”) a Form 25 Notification of Removal from Listing and/or Registration to delist and deregister the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company intends to file a certification on Form 15 with the SEC requesting the deregistration of the Common Stock and the suspension of the Company’s reporting obligations under Sections 13 and 15(d) of the Exchange Act.

 

Item 3.03

Material Modification to Rights of Security Holders.

The information set forth in Item 2.01, Item 3.01 and Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference.

 

Item 5.01

Changes in Control of Registrant.

The information set forth in Item 2.01, Item 3.01 and Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference.

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

In accordance with the terms of the Merger Agreement: (i) each of Kevin Tang, Larry Edwards, Craig Johnson, Laura Johnson, David Ramsay and Robert Rosen resigned from his or her respective position as a member of the Company’s Board of Directors, and any committee thereof, effective at the Effective Time (as defined in the Merger Agreement); and (ii) Kevin Tang, resigned from his position as Chairman of the Company’s Board of Directors.

Effective as of the Effective Time: (i) Pavel Raifeld, CFA, and Marianne Zhen, CPA, became members of the Company’s Board of Directors; (ii) Larry Edwards will remain Chief Executive Officer and President, and “principal executive officer,” as such term is defined under the Exchange Act, of the Company; and (iii) Michael Hearne will remain Chief Financial Officer, and “principal financial officer” and “principal accounting officer,” as such terms are defined under the Exchange Act, of the Company. Information about Mr. Raifeld and Ms. Zhen is contained in the Parent’s and Purchaser’s Offer to Purchase, dated July 25, 2022, which information is incorporated herein by reference. Information about Messrs. Edwards and Hearne is contained in the Company’s Annual Report on Form 10-K, which information is incorporated herein by reference.

 

Item 5.03

Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.

Pursuant to the terms of the Merger Agreement, the certificate of incorporation and bylaws of the Company were amended and restated in their entirety, effective as of the Effective Time. Copies of the Company’s amended and restated certificate of incorporation and amended and restated bylaws are included as Exhibits 3.1 and 3.2 hereto, respectively, each of which is incorporated by reference herein.

 

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    La Jolla Pharmaceutical Company
    By:  

/s/ Larry Edwards

Date: August 22, 2022       Name: Larry Edwards
      Title:   Chief Executive Officer

 

5

EX-3.1 2 d399465dex31.htm EX-3.1 EX-3.1

Exhibit 3.1

AMENDED AND RESTATED

CERTIFICATE OF INCORPORATION OF

LA JOLLA PHARMACEUTICAL COMPANY

* * * * * * * *

ARTICLE I.

The name of the corporation is: La Jolla Pharmaceutical Company (the “Corporation”).

ARTICLE II.

The address of the registered office of the Corporation in the State of Delaware is: Corporation Trust Center, 1209 Orange St., Wilmington, County of New Castle, Delaware, 19801. The name of the registered agent of the Corporation at such address is The Corporation Trust Company.

ARTICLE III.

The nature of the business or purposes to be conducted or promoted by the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware.

ARTICLE IV.

The total number of shares of stock which the Corporation shall have authority to issue is 100 shares of Common Stock, each of which shall have a par value of one cent ($0.01) per share.

ARTICLE V.

In furtherance and not in limitation of the powers conferred by statute, the by-laws of the Corporation may be made, altered, amended or repealed by the stockholders or by a majority of the entire board of directors of the Corporation (the “Board”).

ARTICLE VI.

Elections of directors need not be by written ballot.

ARTICLE VII.

(a) The indemnification and other rights set forth in this Article VII shall not be exclusive of any provisions with respect thereto in the bylaws of the Corporation or any other contract or agreement between the Corporation and any officer, director, employee or agent of the Corporation.

(b) The liability of the directors for monetary damages shall be eliminated to the fullest extent under applicable law. If the General Corporation Law of the State of Delaware is amended after the date hereof to authorize corporate action further eliminating or limiting the personal liability of directors, including with respect to monetary damages, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law of the State of Delaware, as so amended.

(c) To the fullest extent permitted by applicable law, the Corporation is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Corporation (and any other persons to which applicable law permits the Corporation to provide indemnification) through bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise in excess of the indemnification and advancement otherwise permitted by such applicable law. If applicable law is amended after approval by the stockholders of this Article VII to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director to the Corporation shall be eliminated or limited to the fullest extent permitted by applicable law as so amended.

(d) Any repeal or modification of this Article VII shall only be prospective and shall not affect the rights or protections or increase the liability of any director under this Article VII in effect at the time of the alleged occurrence of any act or omission to act giving rise to liability or indemnification; provided, further, neither the amendment nor repeal of this Article VII, nor the adoption of any provision of this Amended and Restated Certificate of Incorporation inconsistent with Article VII, shall eliminate or reduce the effect of this Article VII in respect of any matter occurring before such amendment, repeal or adoption of an inconsistent provision or in respect of any cause of action, suit or claim relating to any such matter which would have given rise to a right of indemnification or right to receive expenses pursuant to this Article VII if such provision had not been so amended or repealed or if a provision inconsistent therewith had not been so adopted.

*    *    *    *

 

- 2 -

EX-3.2 3 d399465dex32.htm EX-3.2 EX-3.2

Exhibit 3.2

LA JOLLA PHARMACEUTICAL COMPANY

INCORPORATED UNDER THE LAWS OF

THE STATE OF DELAWARE

BY-LAWS

ARTICLE I.

OFFICES.

The registered office of La Jolla Pharmaceutical Company (the “Corporation”) shall be located in the state of Delaware and shall be at such address as shall be set forth in the Certificate of Incorporation. The registered agent of the Corporation at such address shall be as set forth in the Certificate of Incorporation. The Corporation may also have such other offices at such other places, within or without the State of Delaware, as the Board of Directors may from time to time designate or the business of the Corporation may require.

ARTICLE II.

STOCKHOLDERS.

Section 1.    Annual Meeting. The annual meeting of stockholders for the election of directors and the transaction of any other business shall be held on such date and at such time and in such place, either within or without the State of Delaware, as shall from time to time be designated by the Board of Directors. At the annual meeting any business may be transacted and any corporate action may be taken, whether stated in the notice of meeting or not, except as otherwise expressly provided by statute or the Certificate of Incorporation.

Section 2.    Special Meetings. Special meetings of the stockholders for any purpose may be called at any time by the Board of Directors, or by the President, and shall be called by the President at the request of the holders of at least 20% of the outstanding shares of capital stock entitled to vote. Special meetings shall be held at such place or places within or without the State of Delaware as shall from time to time be designated by the Board of Directors. At a special meeting no business shall be transacted and no corporate action shall be taken other than that stated in the notice of the meeting.

Section 3.    Notice of Meetings. Written notice of the time and place of any stockholder’s meeting, whether annual or special, shall be given to each stockholder entitled to vote thereat, by personal delivery or by mailing the same to him at his address as the same appears upon the records of the Corporation at least ten (10) days but not more than sixty (60) days before the day of the meeting. Notice of any adjourned meeting need not be given except by announcement at the meeting so adjourned, unless otherwise ordered in connection with such adjournment. Such further notice, if any, shall be given as may be required by law.

Section 4.    Quorum. Any number of stockholders, together holding at least a majority of the capital stock of the Corporation issued and outstanding and entitled to vote, who shall be present in person or represented by proxy at any meeting duly called, shall constitute a quorum for the transaction of all business, except as otherwise provided by law, by the Certificate of Incorporation or by these By-laws.

Section 5.    Adjournment of Meetings. If less than a quorum shall attend at the time for which a meeting shall have been called, the meeting may adjourn from time to time by a majority vote of the stockholders present or represented by proxy and entitled to vote without notice other than by announcement at the meeting until a quorum shall attend. Any meeting at which a quorum is present may also be adjourned in like manner and for such time or upon such call as may be determined by a majority vote of the stockholders present or represented by proxy and entitled to vote. At any adjourned meeting at which a quorum shall be present, any business may be transacted and any corporate action may be taken which might have been transacted at the meeting as originally called.

Section 6.    Voting List. The Secretary shall prepare and make, at least ten (10) days before every election of directors, a complete list of the stockholders entitled to vote, arranged in alphabetical order and showing the address of each stockholder and the number of shares of each stockholder. Such list shall be open at the place where the election is to be held for said ten (10) days, to the examination of any stockholder, and shall be produced and kept at the time and place of election during the whole time thereof, and subject to the inspection of any stockholder who may be present.

Section 7.    Voting. Each stockholder entitled to vote at any meeting may vote either in person or by proxy, but no proxy shall be voted on or after three years from its date, unless said proxy provides for a longer period. Except as otherwise provided by the Certificate of Incorporation, each stockholder entitled to vote shall at every meeting of the stockholders be entitled to one vote for each share of stock registered in his name on the record of stockholders. At all meetings of stockholders all matters, except as otherwise provided by statute, shall be determined by the affirmative vote of the majority of shares present in person or by proxy and entitled to vote on the subject matter. Voting at meetings of stockholders need not be by written ballot.

Section 8.    Record Date of Stockholders. The Board of Directors is authorized to fix in advance a date not exceeding sixty (60) days nor less than ten (10) days preceding the date of any meeting of stockholders, or the date for the payment of any dividend, or the date for the allotment of rights, or the date when any change or conversion or exchange of capital stock shall go into effect, or a date in connection with obtaining the consent of stockholders for any purposes, as a record date for the determination of the stockholders entitled to notice of, and to vote at, any such meeting, and any adjournment thereof, or entitled to receive payment of any such dividend, or to any such allotment of rights, or to exercise the rights in respect of any such change, conversion or exchange of capital stock, or to give such consent, and, in such case, such stockholders and only such stockholders as shall be stockholders of record on the date so fixed shall be entitled to such notice of, and to vote at, such meeting, and any adjournment thereof, or to receive payment of such dividend, or to receive such allotment of rights, or to exercise such rights, or to give such consent, as the case may be, notwithstanding any transfer of any stock on the books of the Corporation, after such record date fixed as aforesaid.

 

-2-

Section 9.    Action Without Meeting. Any action required or permitted to be taken at any annual or special meeting of stockholders may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the Corporation by delivery to its registered office in the State of Delaware, its principal place of business, or an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Delivery made to the Corporation’s registered office shall be by hand or by certified or registered mail, return receipt requested. Prompt notice of the taking of the corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented in writing.

Section 10.    Conduct of Meetings. The Chairman of the Board of Directors, or if there be none, or in the Chairman’s absence, the President shall preside at all regular or special meetings of stockholders. To the maximum extent permitted by law, such presiding person shall have the power to set procedural rules, including but not limited to rules respecting the time allotted to stockholders to speak, governing all aspects of the conduct of such meetings.

ARTICLE III.

DIRECTORS.

Section 1.    Number and Qualifications: The Board of Directors shall consist initially of such number of directors as is set forth in the Statement of the Sole Incorporator, and thereafter shall consist of such number as may be fixed from time to time by resolution of the Board of Directors. The directors need not be stockholders.

Section 2.    Election of Directors: The directors shall be elected by the stockholders at the annual meeting of stockholders.

Section 3.    Duration of Office: The directors chosen at any annual meeting shall, except as hereinafter provided, hold office until the next annual election and until their successors are elected and qualify.

Section 4.    Removal and Resignation of Directors: Except as set forth in the Certificate of Incorporation of the Corporation, as such certificate may be amended by any Certificates of Designation filed by the Corporation, any director may be removed from the Board of Directors, with or without cause, by the holders of a majority of the shares of capital stock entitled to vote, either by written consent or consents or at any special meeting of the stockholders called for that purpose, and the office of such director shall forthwith become vacant.

Any director may resign at any time. Such resignation shall take effect at the time specified therein, and if no time be specified, at the time of its receipt by the President or Secretary. The acceptance of a resignation shall not be necessary to make it effective, unless so specified therein.

 

-3-

Section 5.    Filling of Vacancies: Any vacancy among the directors, occurring from any cause whatsoever, may be filled by a majority of the remaining directors, though less than a quorum, provided, however, that the stockholders removing any director may at the same meeting fill the vacancy caused by such removal, and provided further, that if the directors fail to fill any such vacancy, the stockholders may at any special meeting called for that purpose fill such vacancy. In case of any increase in the number of directors, the additional directors may be elected by the directors in office before such increase.

Any person elected to fill a vacancy shall hold office, subject to the right of removal as hereinbefore provided, until the next annual election and until his successor is elected and qualifies.

Section 6.    Regular Meetings: The Board of Directors shall hold an annual meeting for the purpose of organization and the transaction of any business immediately after the annual meeting of the stockholders, provided a quorum of directors is present. Other regular meetings may be held at such times as may be determined from time to time by resolution of the Board of Directors.

Section 7.    Special Meetings: Special meetings of the Board of Directors may be called by the Chairman of the Board of Directors, if any, or by the President or by any two directors.

Section 8.    Notice and Place of Meetings: Meetings of the Board of Directors may be held at the principal office of the Corporation, or at such other place as shall be stated in the notice of such meeting. Notice of any special meeting, and, except as the Board of Directors may otherwise determine by resolution, notice of any regular meeting also, shall be mailed to each director addressed to him at his residence or usual place of business at least two (2) days before the day on which the meeting is to be held, or if sent to him at such place by facsimile, telegraph or cable, or delivered personally or by telephone, not later than the day before the day on which the meeting is to be held. No notice of the annual meeting of the Board of Directors shall be required if it is held immediately after the annual meeting of the stockholders and if a quorum is present.

Section 9.    Business Transacted at Meetings, etc.: Any business may be transacted and any corporate action may be taken at any regular or special meeting of the Board of Directors at which a quorum shall be present, whether such business or proposed action be stated in the notice of such meeting or not, unless special notice of such business or proposed action shall be required by statute.

Section 10.    Quorum: A majority of the Board of Directors at any time in office shall constitute a quorum. At any meeting at which a quorum is present, the vote of a majority of the members present shall be the act of the Board of Directors unless the act of a greater number is specifically required by law or by the Certificate of Incorporation or these By-laws. The members of the Board of Directors shall act only as the Board of Directors and the individual members thereof shall not have any powers as such.

 

-4-

Section 11.    Compensation: The directors shall not receive any stated salary for their services as directors, but by resolution of the Board of Directors a fixed fee and expenses of attendance may be allowed for attendance at each meeting. Nothing herein contained shall preclude any director from serving the Corporation in any other capacity, as an officer, agent or otherwise, and receiving compensation therefor.

Section 12.    Action Without a Meeting: Any action required or permitted to be taken at any meeting of the Board of Directors, or of any committee thereof, may be taken without a meeting if all members of the Board of Directors or committee, as the case may be, consent thereto in writing, and the writing or writings are filed with the minutes of the proceedings of the Board of Directors or committee.

Section 13.    Meetings Through Use of Communications Equipment: Members of the Board of Directors, or any committee designated by the Board of Directors, shall, except as otherwise provided by law, the Certificate of Incorporation or these By-laws, have the power to participate in a meeting of the Board of Directors, or any committee, by means of a conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and such participation shall constitute presence in person at the meeting.

ARTICLE IV.

COMMITTEES.

Section 1.    Executive Committee: The Board of Directors may, by resolution passed by a majority of the whole Board of Directors, designate two or more of their number to constitute an Executive Committee to hold office at the pleasure of the Board of Directors, which Committee shall, during the intervals between meetings of the Board of Directors, have and exercise all of the powers of the Board of Directors in the management of the business and affairs of the Corporation, subject only to such restrictions or limitations as the Board of Directors may from time to time specify, or as limited by the Delaware Corporation Law, and shall have power to authorize the seal of the Corporation to be affixed to all papers which may require it.

Any member of the Executive Committee may be removed at any time, with or without cause, by a resolution of a majority of the whole Board of Directors.

Any person ceasing to be a director shall ipso facto cease to be a member of the Executive Committee.

Any vacancy in the Executive Committee occurring from any cause whatsoever may be filled from among the directors by a resolution of a majority of the whole Board of Directors.

Section 2.    Other Committees: Other committees, whose members need not be directors, may be appointed by the Board of Directors or the Executive Committee, which committees shall hold office for such time and have such powers and perform such duties as may from time to time be assigned to them by the Board of Directors or the Executive Committee.

 

-5-

Any member of such a committee may be removed at any time, with or without cause, by the Board of Directors or the Executive Committee. Any vacancy in a committee occurring from any cause whatsoever may be filled by the Board of Directors or the Executive Committee.

Section 3.    Resignation: Any member of a committee may resign at any time. Such resignation shall be made in writing and shall take effect at the time specified therein, or, if no time be specified, at the time of its receipt by the President or Secretary. The acceptance of a resignation shall not be necessary to make it effective unless so specified therein.

Section 4.    Quorum: A majority of the members of a committee shall constitute a quorum. The act of a majority of the members of a committee present at any meeting at which a quorum is present shall be the act of such committee. The members of a committee shall act only as a committee, and the individual members thereof shall not have any powers as such.

Section 5.    Record of Proceedings, etc.: Each committee shall keep a record of its acts and proceedings, and shall report the same to the Board of Directors when and as required by the Board of Directors.

Section 6.    Organization, Meetings, Notices, etc.: A committee may hold its meetings at the principal office of the Corporation, or at any other place which a majority of the committee may at any time agreed upon. Each committee may make such rules as it may deem expedient for the regulation and carrying on of its meetings and proceedings. Unless otherwise ordered by the Executive Committee, any notice of a meeting of such committee may be given by the Secretary of the Corporation or by the chairman of the committee and shall be sufficiently given if mailed to each member at his residence or usual place of business at least two (2) days before the day on which the meeting is to be held, or if sent to him at such place by facsimile, telegraph or cable, or delivered personally or by telephone not later than twenty-four (24) hours before the time at which the meeting is to be held.

Section 7.    Compensation: The members of any committee shall be entitled to such compensation as may be allowed them by resolution of the Board of Directors.

ARTICLE V.

OFFICERS.

Section 1.    Number: The officers of the Corporation shall be a President and a Secretary and such other officers as may be appointed in accordance with the provisions of this Article V. The Board of Directors in its discretion may also elect a Chairman of the Board of Directors.

Section 2.    Election, Term of Office and Qualifications: The officers, except as provided in Section 3 of this Article V, shall be chosen annually by the Board of Directors. Each such officer shall, except as herein otherwise provided, hold office until his successor shall have been chosen and shall qualify. The Chairman of the Board of Directors, if any, and the President shall be directors of the Corporation, and should any one of them cease to be a director, he shall ipso facto cease to be such officer. Except as otherwise provided by law, any number of offices may be held by the same person.

 

-6-

Section 3.    Other Officers: Other officers, including one or more vice-presidents, assistant secretaries, treasurer or assistant treasurers, may from time to time be appointed by the Board of Directors, which other officers shall have such powers and perform such duties as may be assigned to them by the Board of Directors or the officer or committee appointing them.

Section 4.    Removal of Officers: Any officer of the Corporation may be removed from office, with or without cause, by a vote of a majority of the Board of Directors.

Section 5.    Resignation: Any officer of the Corporation may resign at any time. Such resignation shall be in writing and shall take effect at the time specified therein, and if no time be specified, at the time of its receipt by the President or Secretary. The acceptance of a resignation shall not be necessary in order to make it effective, unless so specified therein.

Section 6.    Filling of Vacancies: A vacancy in any office shall be filled by the Board of Directors or by the authority appointing the predecessor in such office.

Section 7.    Compensation: The compensation of the officers shall be fixed by the Board of Directors, or by any committee upon whom power in that regard may be conferred by the Board of Directors.

Section 8.    Chairman of the Board of Directors: The Chairman of the Board of Directors, if any, shall be a director and shall preside at all meetings of the stockholders and the Board of Directors, and shall have such power and perform such duties as may from time to time be assigned to him by the Board of Directors.

Section 9.    President: In the absence of the Chairman of the Board of Directors, or if there be none, the President shall preside at all meetings of the stockholders and the Board of Directors. He shall have power to call special meetings of the stockholders or of the Board of Directors or of the Executive Committee at any time. He shall be the chief executive officer of the Corporation, and shall have the general direction of the business, affairs and property of the Corporation, and of its several officers, and shall have and exercise all such powers and discharge such duties as usually pertain to the office of President.

Section 10.    Vice-Presidents: The vice-president, or vice-presidents if there is more than one, shall, subject to the direction of the Board of Directors, at the request of the President or in his absence, or in case of his inability to perform his duties from any cause, perform the duties of the President, and, when so acting, shall have all the powers of, and be subject to all restrictions upon, the President. The vice-presidents shall also perform such other duties as may be assigned to them by the Board of Directors, and the Board of Directors may determine the order of priority among them.

Section 11.    Secretary: The Secretary shall perform such duties as are incident to the office of Secretary, or as may from time to time be assigned to him by the Board of Directors, or as are prescribed by these By-laws.

Section 12.    Treasurer: The Treasurer shall perform such duties and have powers as are usually incident to the office of Treasurer or which may be assigned to him by the Board of Directors.

 

-7-

ARTICLE VI.

CAPITAL STOCK.

Section 1.    No Certificates of Stock: Certificates of capital stock shall be in such form as shall be approved by the Board of Directors. They shall be numbered in the order of their issue and shall be signed by the Chairman of the Board of Directors, the President or one of the vice-presidents, and the Secretary or an assistant secretary or the treasurer or an assistant treasurer, and the seal of the Corporation or a facsimile thereof shall be impressed or affixed or reproduced thereon, provided, however, that where such certificates are signed by a transfer agent or an assistant transfer agent or by a transfer clerk acting on behalf of the Corporation and a registrar, the signature of any such Chairman of the Board of Directors, President, vice-president, Secretary, assistant secretary, treasurer or assistant treasurer may be facsimile. In case any officer or officers who shall have signed, or whose facsimile signature or signatures shall have been used on any such certificate or certificates shall cease to be such officer or officers of the Corporation, whether because of death, resignation or otherwise, before such certificate or certificates shall have been delivered by the Corporation, such certificate or certificates may nevertheless be adopted by the Corporation and be issued and delivered as though the person or persons who signed such certificate or certificates, or whose facsimile signature or signatures shall have been used thereon have not ceased to be such officer or officers of the Corporation. Notwithstanding the foregoing, the capital stock of the Corporation shall initially be uncertificated.

Section 2.    Registration and Transfer of Shares: The name of each person owning a share of the capital stock of the Corporation shall be entered on the books of the Corporation together with the number of shares held by him, her or it, the numbers of the certificates, if any, covering such shares and the dates of acquisition of such shares. The shares of stock of the Corporation held in certificated form shall be transferable on the books of the Corporation by the holders thereof in person, or by their duly authorized attorneys or legal representatives, on surrender and cancellation of certificates for a like number of shares, accompanied by an assignment or power of transfer endorsed thereon or attached thereto, duly executed, and with such proof of the authenticity of the signature as the Corporation or its agents may reasonably require. The shares of stock of the Corporation that are not held in certificated form shall be transferable on the books of the Corporation by the holders thereof in person, or by their duly authorized attorneys or legal representatives, on delivery of an assignment or power of transfer. A record shall be made of each transfer.

The Board of Directors may make other and further rules and regulations concerning the transfer and registration of certificates for stock and may appoint a transfer agent or registrar or both and may require all certificates of stock to bear the signature of either or both.

Section 3.    Lost, Destroyed and Mutilated Certificates: The holder of any stock of the Corporation held in certificated form shall immediately notify the Corporation of any loss, theft, destruction or mutilation of the certificates therefor. The Corporation may issue a new certificate of stock in the place of any certificate theretofore issued by it and alleged to have been lost, stolen or destroyed, and the Board of Directors may, in its discretion, require the owner of the lost, stolen or destroyed certificate, or the owner’s legal representatives, to give the Corporation a bond, in such sum not exceeding double the value of the stock and with such surety or sureties

 

-8-

as they may require, to indemnify it against any claim that may be made against it by reason of the issue of such new certificate and against all other liability in the premises, or may remit such owner to such remedy or remedies as he may have under the laws of the State of Delaware.

ARTICLE VII.

DIVIDENDS, SURPLUS, ETC.

Section 1.    General Discretion of Directors: The Board of Directors shall have power to fix and vary the amount to be set aside or reserved as working capital of the Corporation, or as reserves, or for other proper purposes of the Corporation, and, subject to the requirements of the Certificate of Incorporation, to determine whether any, if any, part of the surplus or net profits of the Corporation shall be declared as dividends and paid to the stockholders, and to fix the date or dates for the payment of dividends.

ARTICLE VIII.

MISCELLANEOUS PROVISIONS.

Section 1.    Fiscal Year: The fiscal year of the Corporation shall commence on the first day of January and end on the last day of December.

Section 2.    Corporate Seal: The corporate seal shall be in such form as approved by the Board of Directors and may be altered at their pleasure. The corporate seal may be used by causing it or a facsimile thereof to be impressed or affixed or reproduced or otherwise.

Section 3.    Notices: Except as otherwise expressly provided, any notice required by these By-laws to be given shall be sufficient if given by depositing the same in a post office or letter box in a sealed postpaid wrapper addressed to the person entitled thereto at his address, as the same appears upon the books of the Corporation, or by sending via facsimile, telegraphing or cabling the same to such person at such addresses; and such notice shall be deemed to be given at the time it is mailed, sent via facsimile, telegraphed or cabled.

Section 4.    Waiver of Notice: Any stockholder or director may at any time, by writing or by telegraph or by cable, waive any notice required to be given under these By-laws, and if any stockholder or director shall be present at any meeting his presence shall constitute a waiver of such notice.

Section 5.    Checks, Drafts, etc.: All checks, drafts or other orders for the payment of money, notes or other evidences of indebtedness issued in the name of the Corporation, shall be signed by such officer or officers, agent or agents of the Corporation, and in such manner, as shall from time to time be designated by resolution of the Board of Directors.

Section 6.    Deposits: All funds of the Corporation shall be deposited from time to time to the credit of the Corporation in such bank or banks, trust companies or other depositories as the Board of Directors may select, and, for the purpose of such deposit, checks, drafts, warrants and other orders for the payment of money which are payable to the order of the Corporation, may be endorsed for deposit, assigned and delivered by any officer of the Corporation, or by such agents of the Corporation as the Board of Directors or the President may authorize for that purpose.

 

-9-

Section 7.    Voting Stock of Other Corporations: Except as otherwise ordered by the Board of Directors or the Executive Committee, the President or the treasurer shall have full power and authority on behalf of the Corporation to attend and to act and to vote at any meeting of the stockholders of any corporation of which the Corporation is a stockholder and to execute a proxy to any other person to represent the Corporation at any such meeting, and at any such meeting the President or the treasurer or the holder of any such proxy, as the case may be, shall possess and may exercise any and all rights and powers incident to ownership of such stock and which, as owner thereof, the Corporation might have possessed and exercised if present. The Board of Directors or the Executive Committee may from time to time confer like powers upon any other person or persons.

Section 8.    Indemnification of Officers and Directors: The Corporation shall indemnify any and all of its directors or officers, including former directors or officers, and any employee, who shall serve as an officer or director of any corporation at the request of this Corporation, to the fullest extent permitted under and in accordance with the laws of the State of Delaware.

ARTICLE IX.

AMENDMENTS.

The Board of Directors shall have the power to make, rescind, alter, amend and repeal these By-laws, provided, however, that the stockholders shall have power to rescind, alter, amend or repeal any by-laws made by the Board of Directors, and to enact by-laws which if so expressed shall not be rescinded, altered, amended or repealed by the Board of Directors. No change of the time or place for the annual meeting of the stockholders for the election of directors shall be made except in accordance with the laws of the State of Delaware.

*            *             *            *            *

 

-10-

EX-101.SCH 4 ljpc-20220822.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 ljpc-20220822_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 6 ljpc-20220822_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Aug. 22, 2022
Cover [Abstract]  
Entity Registrant Name LA JOLLA PHARMACEUTICAL CO
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0000920465
Current Fiscal Year End Date --12-31
Document Type 8-K
Document Period End Date Aug. 22, 2022
Entity Incorporation State Country Code DE
Entity File Number 001-36282
Entity Tax Identification Number 33-0361285
Entity Address, Address Line One 201 Jones Road
Entity Address, Address Line Two Suite 400
Entity Address, City or Town Waltham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02451
City Area Code (617)
Local Phone Number 715-3600
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol LJPC
Entity Emerging Growth Company false
XML 8 d399465d8k_htm.xml IDEA: XBRL DOCUMENT 0000920465 2022-08-22 2022-08-22 LA JOLLA PHARMACEUTICAL CO NASDAQ false 0000920465 --12-31 8-K 2022-08-22 DE 001-36282 33-0361285 201 Jones Road Suite 400 Waltham MA 02451 (617) 715-3600 false false false false Common Stock, par value $0.0001 per share LJPC false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName, dei:SecurityExchangeName - d399465d8k.htm 7 d399465d8k.htm d399465dex31.htm d399465dex32.htm ljpc-20220822.xsd ljpc-20220822_lab.xml ljpc-20220822_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d399465d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d399465d8k.htm" ] }, "labelLink": { "local": [ "ljpc-20220822_lab.xml" ] }, "presentationLink": { "local": [ "ljpc-20220822_pre.xml" ] }, "schema": { "local": [ "ljpc-20220822.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 5, "total": 5 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ljpc", "nsuri": "http://www.lajollapharmaceutical.com/20220822", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d399465d8k.htm", "contextRef": "duration_2022-08-22_to_2022-08-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d399465d8k.htm", "contextRef": "duration_2022-08-22_to_2022-08-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.lajollapharmaceutical.com//20220822/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-22-226110-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-226110-xbrl.zip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end